Fusions between dendritic cells and whole tumor cells as anticancer vaccines

OncoImmunology

Volumn 2, Issue 5, 2013, Pages

  Koido, Shigeo ^a   Homma, Sadamu ^a   Okamoto, Masato ^b   Namiki, Yoshihisa ^a   Takakura, Kazuki ^a   Uchiyama, Kan ^a   Kajihara, Mikio ^a   Arihiro, Seiji ^a   Imazu, Hiroo ^a   Arakawa, Hiroshi ^a   Kan, Shin ^a   Komita, Hideo ^a   Ito, Masaki ^a   Ohkusa, Toshifumi ^a   Gong, Jianlin ^c   Tajiri, Hisao ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticancer vaccines; Cell fusions; Dendritic cells

Indexed keywords

CANCER CELL DENDRITIC CELL FUSION VACCINE; CANCER VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER IMMUNIZATION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUSION; CELL SURFACE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DOWN REGULATION; DRUG EFFICACY; DRUG POTENCY; HLA TYPING; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; LYMPHOCYTE ACTIVATION; MOLECULAR DYNAMICS; NONHUMAN; SIGNAL TRANSDUCTION; VACCINE PRODUCTION;

EID: 84885192432     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.24437     Document Type: Article

References (16)

1. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991; 9:271-96; PMID:1910679; http://dx.doi.org/10.1146/annurev.iy.09.040191.001415
2. Nestle FO, Alijagic S, Gilliet M, Sun Y, Grabbe S, Dummer R, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4:328-32; PMID:9500607; http://dx.doi.org/10.1038/nm0398-328
3. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr. Peptide-pulsed dendritic cells induce antigen- specific CTL-mediated protective tumor immunity. J Exp Med 1996; 183:283-7; PMID:8551233; http://dx.doi.org/10.1084/jem.183.1.283
4. Phan V, Errington F, Cheong SC, Kottke T, Gough M, Altmann S, et al. A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines. Nat Med 2003; 9:1215-9; PMID:12925849; http://dx.doi. org/10.1038/nm923
5. Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J Exp Med 1996; 183:317-22; PMID:8551239; http://dx.doi.org/10.1084/jem.183.1.317
6. Russo V, Tanzarella S, Dalerba P, Rigatti D, Rovere P, Villa A, et al. Dendritic cells acquire the MAGE- 3 human tumor antigen from apoptotic cells and induce a class I-restricted T cell response. Proc Natl Acad Sci U S A 2000; 97:2185-90; PMID:10681453; http://dx.doi.org/10.1073/pnas.040540197
7. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat Med 1997; 3:558-61; PMID:9142127; http://dx.doi.org/10.1038/nm0597-558
8. Gong J, Koido S, Calderwood SK. Cell fusion: from hybridoma to dendritic cell-based vaccine. Expert Rev Vaccines 2008; 7:1055-68; PMID:18767954; http://dx.doi.org/10.1586/14760584.7.7.1055
9. Koido S, Tanaka Y, Chen D, Kufe D, Gong J. The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1-transgenic mice. J Immunol 2002; 168:2111-7; PMID:11859096
10. Koido S, Ohana M, Liu C, Nikrui N, Durfee J, Lerner A, et al. Dendritic cells fused with human cancer cells: morphology, antigen expression, and T cell stimulation. Clin Immunol 2004; 113:261-9; PMID:15507391; http://dx.doi.org/10.1016/j. clim.2004.08.004
11. Koido S, Gong J. Characterization of structure and direct antigen presentation by dendritic/tumorfused cells as cancer vaccines. Anticancer Res 2013; 33:347-54; PMID:23393323
12. Koido S, Hara E, Homma S, Torii A, Toyama Y, Kawahara H, et al. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Clin Cancer Res 2005; 11:7891-900; PMID:16278414; http://dx.doi.org/10.1158/1078-0432.CCR-05-1330
13. Koido S, Homma S, Hara E, Namiki Y, Takahara A, Komita H, et al. Regulation of tumor immunity by tumor/dendritic cell fusions. Clin Dev Immunol 2010; 2010:516768; PMID:21048993; http://dx.doi. org/10.1155/2010/516768
14. Koido S, Homma S, Okamoto M, Namiki Y, Takakura K, Takahara A, et al. Combined TLR2/4-activated dendritic/tumor cell fusions induce augmented cytotoxic T lymphocytes. PLoS ONE 2013; 8:e59280; http://dx.doi.org/10.1371/journal. pone.0059280
15. Koido S, Hara E, Homma S, Torii A, Mitsunaga M, Yanagisawa S, et al. Streptococcal preparation OK-432 promotes fusion efficiency and enhances induction of antigen-specific CTL by fusions of dendritic cells and colorectal cancer cells. J Immunol 2007; 178:613-22; PMID:17182602
16. Koido S, Hara E, Homma S, Mitsunaga M, Takahara A, Nagasaki E, et al. Synergistic induction of antigenspecific CTL by fusions of TLR-stimulated dendritic cells and heat-stressed tumor cells. J Immunol 2007; 179:4874-83; PMID:17878387